MCID: CHR072
MIFTS: 59

Chordoma malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Chordoma

About this section
Sources:
12diseasecard, 24GeneTests, 25Genetics Home Reference, 26GTR, 30ICD10 via Orphanet, 36MedGen, 38MeSH, 39MESH via Orphanet, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Chordoma:

Name: Chordoma 51 47 24 25 53 69 12 49 38 67
Chordoma, Susceptibility to 51 26
Notochordal Sarcoma 25 53
Chdm 25 69
 
Chordoepithelioma 25
Chordocarcinoma 25
Notochordoma 25

Characteristics:

Orphanet epidemiological data:

53
chordoma:
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adult; Age of death: any age

HPO:

63
chordoma:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM51 215400
Orphanet53 ORPHA178
MESH via Orphanet39 D002817
UMLS via Orphanet68 C0008487
ICD10 via Orphanet30 C76.7
MedGen36 C0008487
MeSH38 D002817

Summaries for Chordoma

About this section
NIH Rare Diseases:47 A chordoma is a rare tumor that develops from cells of the notochord, a structure that is present in the developing embryo and is important for the development of the spine. The notochord usually disappears before birth, though a few cells may remain embedded in the bones of the spine or at the base of the skull. Chordomas can occur anywhere along the spine. Approximately half of all chordomas occur at the base of the spine; approximately one third occur at the base of the skull. Chordomas grow slowly, extending gradually into the surrounding bone and soft tissue. The actual symptoms depend on the location of the chordoma. A chordoma at the base of the skull may lead to double vision and headaches. A chordoma that occurs at the base of the spine may cause problems with bladder and bowel function. Chordomas typically occur in adults between the ages of 40 and 70. In many cases, the cause of the chordoma remains unknown. Recent studies have shown that changes in the T gene have been associated with chordomas in a small set of families. In these families an inherited duplication of the T gene is associated with an increased risk of developing a chordoma. The current treatment is often the surgical removal of the tumor, followed by radiotherapy. Last updated: 11/9/2016

MalaCards based summary: Chordoma, also known as chordoma, susceptibility to, is related to parachordoma and herpes simplex, and has symptoms including abnormality of the head, abnormality of the vertebral column and chordoma. An important gene associated with Chordoma is CHDM (Chordoma), and among its related pathways are Advanced glycosylation endproduct receptor signaling and Cytoskeleton remodeling Neurofilaments. Affiliated tissues include bone, lung and liver, and related mouse phenotypes are normal and neoplasm.

Genetics Home Reference:25 A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordomas grow slowly, gradually extending into the bone and soft tissue around them. They often recur after treatment, and in about 40 percent of cases the cancer spreads (metastasizes) to other areas of the body, such as the lungs.

OMIM:51 Chordomas are rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the... (215400) more...

UniProtKB/Swiss-Prot:69 Chordoma: Rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the spinal axis, predominantly in the sphenooccipital, vertebral and sacrococcygeal regions. They are characterized by slow growth, local destruction of bone, extension into adjacent soft tissues and rarely, distant metastatic spread.

Wikipedia:70 Chordoma is a rare slow-growing neoplasm thought to arise from cellular remnants of the notochord. The... more...

Related Diseases for Chordoma

About this section

Diseases related to Chordoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 241)
idRelated DiseaseScoreTop Affiliating Genes
1parachordoma30.6DES, MUC1, VIM
2herpes simplex29.7CDKN2A, EGFR, MET
3chondroma29.6CDH1, CDKN2A, EGFR
4plasmacytoma29.4CDH1, CDKN2A, EGFR
5renal cell carcinoma29.0CDH1, EGFR, MET, MUC1, VIM
6chondroid chordoma12.2
7clivus chordoma12.2
8spinal chordoma12.2
9clivus chondroid chordoma12.1
10sacrum chordoma12.1
112q33.1 microdeletion syndrome10.8MUC1, VIM
12logopenic progressive aphasia10.7MUC1, S100B
13intermediate dend syndrome10.7MUC1, S100B
14transitional meningioma10.7MUC1, VIM
15hypotonia10.6S100B, VIM
16exstrophy-epispadias complex10.6S100B, VIM
17pituitary deficiency due to rathke's pouch cysts10.6MUC1, S100B
18harding ataxia10.6DES, VIM
19fraxf syndrome10.6S100B, VIM
20skin sarcoma10.6MUC1, VIM
21intravascular fasciitis10.6DES, MUC1
22lymphocytic vasculitis10.6DES, VIM
23combined thymoma10.6DES, MUC1
24sm-ahnmd10.6MET, VIM
25skin lipoma10.6DES, VIM
26malignant cystic nephroma10.6S100B, VIM
27salcedo syndrome10.6DES, GFAP
28pancreatic delta cell neoplasm10.6DES, VIM
29anterograde amnesia10.5DES, VIM
30amelogenesis imperfecta local hypoplastic10.5CDKN2A, VIM
31mollaret meningitis10.5DES, VIM
32bickerstaff brainstem encephalitis10.5DES, S100B
33glottis verrucous carcinoma10.5EGFR, MUC1
34gallbladder squamous cell carcinoma10.5CDKN2A, MET
35anaplastic oligoastrocytoma10.5MUC1, S100B, VIM
36pediculus humanus capitis infestation10.5MUC1, S100B, VIM
37intracystic papillary adenoma10.5GFAP, S100B
38eccrine papillary adenoma10.5MUC1, S100B, VIM
39l-cell glucagon-like peptide producing tumor10.5MUC1, S100B, VIM
40plethora of newborn10.5CDH1, MUC1
41pseudosarcomatous fibromatosis10.5MUC1, NCAM1
42hemiplegia alterans10.5GFAP, S100B
43congenital structural myopathy10.5GFAP, MUC1, VIM
44dens in dente and palatal invaginations10.5MUC1, S100B, VIM
45pineoblastoma10.5GFAP, MUC1, VIM
46glioma susceptibility 110.5MUC1, S100B, VIM
47middle ear squamous cell carcinoma10.4CDH1, VIM
48acute serous otitis media10.4MUC1, S100B, VIM
49vascular hemostatic disease10.4GFAP, MUC1, VIM
50luminal breast carcinoma10.4EGFR, MUC1

Graphical network of the top 20 diseases related to Chordoma:



Diseases related to chordoma

Symptoms for Chordoma

About this section

Symptoms by clinical synopsis from OMIM:

215400

Clinical features from OMIM:

215400

Human phenotypes related to Chordoma:

 63
id Description HPO Frequency HPO Source Accession
1 abnormality of the head63 HP:0000234
2 abnormality of the vertebral column63 HP:0000925
3 chordoma63 HP:0010762

Drugs & Therapeutics for Chordoma

About this section

Drugs for Chordoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 2500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
TrioxsalenapprovedPhase 2, Phase 1413902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
3
nivolumabapprovedPhase 2, Phase 1326946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
4
Dasatinibapproved, investigationalPhase 2281302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
5Imatinib MesylatePhase 2, Phase 1594123596
6Protein Kinase InhibitorsPhase 2, Phase 13612
7Immunosuppressive AgentsPhase 2, Phase 112770
8Angiogenesis InhibitorsPhase 24143
9Angiogenesis Modulating AgentsPhase 24072
10Hematoporphyrin DerivativePhase 2, Phase 130
11HematoporphyrinsPhase 2, Phase 114
12Photosensitizing AgentsPhase 2, Phase 1476
13Dihematoporphyrin EtherPhase 2, Phase 141
14Pharmaceutical SolutionsPhase 27793
15EtherPhase 2, Phase 160
16AntibodiesPhase 2, Phase 16045
17Antibodies, MonoclonalPhase 2, Phase 13795
18VaccinesPhase 26428
19ImmunoglobulinsPhase 2, Phase 16045
20Dermatologic AgentsPhase 2, Phase 15674
21
CobaltPhase 21657440-48-4104729
Synonyms:
Aquacat
Co
 
Cobalt-59
Cobatope-57
Kobalt
Super cobalt
22Brewer's YeastNutraceuticalPhase 232
23lysineNutraceuticalPhase 2, Phase 190
24
Panobinostatapproved, investigationalPhase 1136404950-80-76918837
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
panobinostat
25
Cyclophosphamideapproved, investigationalPhase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
26
LenograstimapprovedPhase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
27
MelphalanapprovedPhase 1712148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
28
Amifostineapproved, investigationalPhase 18120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065
29
Busulfanapproved, investigationalPhase 154055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
30
ThiotepaapprovedPhase 121652-24-45453
Synonyms:
 
Thioplex
31Protective AgentsPhase 17190
32MitogensPhase 11526
33Adjuvants, ImmunologicPhase 12484
34Histone Deacetylase InhibitorsPhase 1566
35Alkylating AgentsPhase 14694
36Antineoplastic Agents, AlkylatingPhase 14474
37Antirheumatic AgentsPhase 110627
38Radiation-Protective AgentsPhase 1466
39Liver ExtractsPhase 13868
40
Hyaluronic acidapproved, vet_approved4399004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
41
Mentholapproved23532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
42Blood Substitutes246
43Viscosupplements364
44Povidone157
45Plasma Substitutes233
46Misonidazole22
47Anti-Infective Agents21402
48Antiparasitic Agents2127
49Antiprotozoal Agents1986

Interventional clinical trials:

(show all 39)
idNameStatusNCT IDPhase
1Stereotactic Body Radiotherapy for Spine TumorsActive, not recruitingNCT01347307Phase 4
2Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
3Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull BaseRecruitingNCT01182779Phase 3
4Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant TumorsNot yet recruitingNCT02838602Phase 3
5Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical SpineUnknown statusNCT00592748Phase 1, Phase 2
6Efficacy and Safety of Imatinib in ChordomaCompletedNCT00150072Phase 2
7Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
8Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
9Ion Irradiation of Sacrococcygeal ChordomaRecruitingNCT01811394Phase 2
10Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersRecruitingNCT02802969Phase 2
11The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, ChordomaRecruitingNCT02383498Phase 2
12Proton Radiation for Chordomas and ChondrosarcomasRecruitingNCT01449149Phase 1, Phase 2
13High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of SkullRecruitingNCT01346124Phase 2
14A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasRecruitingNCT02389244Phase 2
15A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaRecruitingNCT02601950Phase 2
16Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
17Photodynamic Therapy (PDT) For Recurrent High Grade GliomasRecruitingNCT01966809Phase 2
18Proton Beam Therapy for Chordoma PatientsActive, not recruitingNCT00496119Phase 2
19Trial of Dasatinib in Advanced SarcomasActive, not recruitingNCT00464620Phase 2
20Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaUnknown statusNCT01175109Phase 1
21Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
22A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaRecruitingNCT02601937Phase 1
23HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid TumorsRecruitingNCT00931931Phase 1
24Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard TherapiesRecruitingNCT01924689Phase 1
25Photodynamic Therapy (PDT) for Recurrent Pediatric Brain TumorsRecruitingNCT01682746Phase 1
26Nilotinib With Radiation for High Risk ChordomaActive, not recruitingNCT01407198Phase 1
27Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaNot yet recruitingNCT02989636Phase 1
28Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid TumorsTerminatedNCT00003926Phase 1
29Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With CancerUnknown statusNCT00349024
30Chordoma Family StudyCompletedNCT00410670
31Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma FamiliesCompletedNCT00341627
32Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With ChordomasCompletedNCT00713037
33Proton Therapy for Chordomas and/or ChondrosarcomasCompletedNCT00797602
34Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue SarcomasCompletedNCT01567046
35Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility GenesRecruitingNCT01200680
36A Study of IMRT in Primary Bone and Soft Tissue SarcomaRecruitingNCT02520128
37Effect of High Doses of Radiation on Bone Structure and MetabolismRecruitingNCT02323295
38Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue SarcomaRecruitingNCT00919269
39Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized DiseaseNot yet recruitingNCT02986516

Search NIH Clinical Center for Chordoma


Cochrane evidence based reviews: chordoma

Genetic Tests for Chordoma

About this section

Genetic tests related to Chordoma:

id Genetic test Affiliating Genes
1 Chordoma26 24

Anatomical Context for Chordoma

About this section

MalaCards organs/tissues related to Chordoma:

35
Bone, Lung, Liver, Brain, Bone marrow, Pituitary, Thyroid

Animal Models for Chordoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Chordoma:

40 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00028738.2CDH1, EGFR, GFAP, MET, PDGFRA, S100B
2MP:00020068.1CDH1, CDKN2A, EGFR, LGALS3, MET, PDGFRA
3MP:00053867.7CDKN2A, DES, GFAP, LGALS3, MET, NCAM1
4MP:00107717.6CDH1, CDKN2A, EGFR, JUP, LGALS3, PDGFRA
5MP:00053697.6CDKN2A, DES, EGFR, GFAP, JUP, MET
6MP:00053817.6CDH1, CDKN2A, EGFR, GFAP, LGALS3, MET
7MP:00053807.5CDH1, CDKN2A, EGFR, JUP, MET, PDGFRA
8MP:00053877.1CDH1, CDKN2A, EGFR, GFAP, JUP, LGALS3
9MP:00053887.1CDKN2A, EGFR, JUP, LGALS3, MET, PDGFRA
10MP:00036316.9CDKN2A, EGFR, GFAP, JUP, LGALS3, MET
11MP:00053856.6CDH1, CDKN2A, DES, EGFR, GFAP, JUP
12MP:00053846.4CDH1, CDKN2A, DES, EGFR, GFAP, JUP
13MP:00053766.2CDH1, CDKN2A, DES, EGFR, GFAP, JUP
14MP:00107686.1CDH1, CDKN2A, DES, EGFR, GFAP, JUP

Publications for Chordoma

About this section

Articles related to Chordoma:

(show top 50)    (show all 761)
idTitleAuthorsYear
1
C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum-a single center pilot study. (27091202)
2016
2
Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. (25755752)
2015
3
Anaplastic chordoma with loss of INI1 and brachyury expression in a 2-year-old girl. (25074874)
2014
4
Comparison of human chordoma cell-kill for 290 MeV/n carbon ions versus 70 MeV protons in vitro. (23587329)
2013
5
Differentiation of primary chordoma, giant cell tumor and schwannoma of the sacrum by CT and MRI. (24035342)
2013
6
Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets. (23776758)
2013
7
Wide resection of sacral chordoma via a posterior approach. (22038441)
2012
8
Intradural chordoma mimicking a lateral sphenoid wing meningioma: a case report. (23319197)
2012
9
A rare case of jugular foramen chordoma with an unusual extension. (21576564)
2011
10
Total en bloc spondylectomy for L2 chordoma: a case report. (21928701)
2011
11
Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression. (20617367)
2011
12
PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma. (21955928)
2011
13
Primary extranotochordal cervical chordoma masquerading as a thyroid neoplasm: a case report. (21053549)
2010
14
Intradural cranial chordoma. (20860957)
2010
15
Surgery significantly improves survival in patients with chordoma. (20042964)
2010
16
Molecular characterization of putative chordoma cell lines. (21253487)
2010
17
Total resection of inferiorly located sacral chordoma with posterior only approach: case report and review of the literature. (20963705)
2010
18
Chordoma and chondrosarcoma gene profile: implications for immunotherapy. (18641983)
2009
19
Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. (19521276)
2009
20
Chordoma with increased prolactin levels (pseudoprolactinoma) mimicking pituitary adenoma: a case report with review of the literature. (20160370)
2009
21
Dedifferentiated chordoma with a sarcomatous component: an overlooked diagnosis. (20364771)
2009
22
Safety margins in resection of sacral chordoma: analysis of 18 patients. (18568352)
2009
23
Transrectal EUS-guided FNA biopsy of a presacral chordoma--report of a case and review of the literature. (18442211)
2008
24
Expression of hepatocyte growth factor and c-MET in skull base chordoma. (17948912)
2008
25
Chordoma: a rare presentation as solitary ivory vertebra. (18296805)
2008
26
Entire infrasellar craniopharyngioma simulating clival chordoma. (18036439)
2007
27
Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis. (18095132)
2007
28
Chordoma cutis. (18076624)
2007
29
Intradural cranial chordoma: a rare presentation of an uncommon tumor. Surgical experience and review of the literature. (17410711)
2007
30
Total en bloc spondylectomy of C5 vertebra for chordoma. (17450062)
2007
31
Spinal chordoma of the dorslumbar junction. (16883772)
2006
32
Chordoma detected on F-18 FDG PET. (16855447)
2006
33
Extra-axial chordoma. (17149966)
2006
34
Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. (16222158)
2005
35
Disappearance of a cervical spine chordoma after nonoperative treatment. A case report. (16085625)
2005
36
Soft tissue sacrococcygeal chordoma with intracytoplasmic filamentous inclusions. (16325512)
2005
37
Histogenesis of intralesional fibrous septum in chordoma. (16136750)
2005
38
FNAC diagnosis of a pre-sacral chordoma: a case report. (16758685)
2005
39
Chondroid chordoma of the nasal septum. (12578458)
2003
40
Spinal chordoma of the terminal filum. Case report. (12450288)
2002
41
Chordoma. (11827649)
2002
42
Chordoma in the sella turcica. (12160311)
2002
43
Crush preparation findings of "sarcomatoid" chordoma of the sacrum: report of a case with histologic, immunohistochemical, and ultrastructural correlation. (11747239)
2001
44
Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression. (9195570)
1997
45
Significance of immunohistochemical study in the diagnosis and differential diagnosis of chordoma]. (8697996)
1995
46
Immunohistochemical and electron microscopic studies on intracranial chordomas: difference between typical chordomas and chondroid chordomas. (7512865)
1994
47
Immunohistochemical and ultrastructural study of skull base chordomas. (7512866)
1994
48
Immunohistochemistry of ecchordosis physaliphora and chordoma. (1703453)
1990
49
The nature of cytoplasmic vacuoles in chordoma cells. A correlative enzyme and electron microscopic histochemical study. (2287590)
1990
50
Chondroid chordoma: a low-grade chondrosarcoma and its differential diagnosis. (2673669)
1989

Variations for Chordoma

About this section

Copy number variations for Chordoma from CNVD:

6 (show top 50)    (show all 470)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
113362101135374737LossPTENChordoma
21337217122200000LossNF1Chordoma
31337317122200000LossP53Chordoma
41379511151400000LossWT1Chordoma
51381019163811651GainBAXChordoma
61381119163811651GainTGFB1Chordoma
71382518176117153LossSMAD4Chordoma
8174031142600000180300000GainChordoma
921008115600000106368585LossChordoma
10216541316000000114142980LossBRCA2Chordoma
11216551316000000114142980LossRBChordoma
12257391193800000243700000GainChordoma
1328392172220000078774742GainHER2Chordoma
142928912300000124300000LossRUNX3Chordoma
153107412522600125291501LossRUNX3Chordoma
163134812697957526979875GainChordoma
173173313024567130246671GainChordoma
183190113189933431900334LossChordoma
193190813194031531941315GainChordoma
203203113271974532720045GainChordoma
213203213272003632721036LossChordoma
223220713445134634452346GainChordoma
233267513839955038400550GainChordoma
243277013926412239265122GainChordoma
253396615099200250993002GainChordoma
2635065115970000074900000GainMEN1Chordoma
273603617090172070902020LossChordoma
283603817099838170998681LossChordoma
293607517113772871138728GainChordoma
304831211112700000LossChordoma
314958111108093558108239826LossATMChordoma
3252925112170000048800000LossChordoma
3356520115990000068400000LossChordoma
346373612120700000125900000LossChordoma
3565974122368523024715380GainSOX5Chordoma
3666550123070000035800000LossChordoma
37676771243829014414522GainCCND2Chordoma
38678471245433084554780GainChordoma
3968279124836674748398285GainCOL2A1Chordoma
407431113103858404103859404LossChordoma
418141414102320080102321080GainChordoma
428183514104931320104931620GainChordoma
438183614104931398104932398LossChordoma
4486968146789203367893033LossChordoma
4586969146789468567895685GainChordoma
4686990146827123268272232GainChordoma
4787006146840833268409332GainChordoma
4887676147586412775864427LossChordoma
4987678147588700575888005GainChordoma
5087692147618426376185263LossChordoma

Expression for genes affiliated with Chordoma

About this section
Search GEO for disease gene expression data for Chordoma.

Pathways for genes affiliated with Chordoma

About this section

Pathways related to Chordoma according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
19.8LGALS3, S100B
2
Show member pathways
9.6DES, GFAP, VIM
39.5NCAM1, PDGFRA, T
49.4LGALS3, MUC1, NCAM1
59.2EGFR, NCAM1
69.1CDH1, EGFR
79.0MET, NCAM1, T, VIM
89.0CDH1, MET, NCAM1
99.0CDH1, JUP, MET
108.9CDH1, DES, JUP, VIM
118.9GFAP, NCAM1, PDGFRA, S100B, VIM
128.9EGFR, MET, VIM
138.8CDH1, JUP, MUC1, NCAM1
148.8EGFR, MET, PDGFRA
158.7EGFR, GFAP, LGALS3, VIM
168.7CDKN2A, EGFR, PDGFRA
178.6CDH1, EGFR, MET
188.6CDH1, EGFR, MET
198.6CDH1, EGFR, MET
208.5CDH1, CDKN2A, EGFR
217.9CDKN2A, EGFR, MET, PDGFRA, VIM
22
Show member pathways
7.6CDH1, CDKN2A, EGFR, MET, PDGFRA
237.2CDH1, CDKN2A, EGFR, JUP, MET, PDGFRA
24
Show member pathways
6.5CDH1, CDKN2A, DES, EGFR, GFAP, MET

GO Terms for genes affiliated with Chordoma

About this section

Cellular components related to Chordoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1fascia adherensGO:000591610.2DES, JUP
2intermediate filament cytoskeletonGO:004511110.1DES, GFAP, VIM
3catenin complexGO:001634210.1CDH1, JUP
4intermediate filamentGO:00058829.7DES, GFAP, JUP, VIM
5cytoplasmGO:00057375.3CDH1, CDKN2A, DES, EGFR, GFAP, JUP

Biological processes related to Chordoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Bergmann glial cell differentiationGO:006002010.4GFAP, VIM
2intermediate filament-based processGO:004510310.4GFAP, VIM
3astrocyte developmentGO:00140029.9GFAP, VIM
4cellular response to indole-3-methanolGO:00716819.7CDH1, JUP
5intermediate filament organizationGO:00451099.3DES, GFAP, VIM
6single organismal cell-cell adhesionGO:00163378.6CDH1, EGFR, JUP

Molecular functions related to Chordoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1structural constituent of cytoskeletonGO:00052009.6DES, GFAP, VIM
2Ras guanyl-nucleotide exchange factor activityGO:00050888.8EGFR, NCAM1, PDGFRA
3protein phosphatase bindingGO:00199038.7EGFR, JUP, MET
4glycoprotein bindingGO:00019488.3CDH1, EGFR, GFAP, VIM

Sources for Chordoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet